VCBeat Health Contact Us
Home Merck Reports Q3 2019 Results: Keytruda Hits $3.07B in Global Sales, China Revenue Surges 90%

Merck Reports Q3 2019 Results: Keytruda Hits $3.07B in Global Sales, China Revenue Surges 90%

Oct 30, 2019 10:10 CST Updated 10:10
MSD

Pharmaceutical R&D and Manufacturer

On October 29, MSD released its Q3 2019 earnings report. Global sales revenue for the first three quarters amounted to $34.972 billion, with Q3 sales revenue reaching $12.4 billion, a year-on-year increase of 15%.

Keytruda’s global sales in the third quarter amounted to $3.07 billion, representing a 62% year-over-year increase, with total sales for the first three quarters of 2019 reaching $7.973 billion. Global sales of Gardasil/Gardasil 9 for the first three quarters reached $3.044 billion.

MSD’s Core Drug Sales in the First Three Quarters of 2019 (USD billion)

MSD’s China business generated revenues of $2.368 billion in the first three quarters of 2019, with Q3 sales reaching $898 million, an 84% year-over-year increase, surpassing Japan. Excluding the adverse impact of foreign exchange fluctuations, the year-over-year growth was 90%. This performance was primarily driven by Keytruda and Gardasil/Gardasil 9.

*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.